GlassScriptPhysician profile
James Brandon Emery
NPI 1346447919
$978.13
in general payments reported to CMS, 2019-2025
28 companies · $262 in 2025
The $262 reported for 2025 was more than what 81% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $61.39 · 2023: $104 · 2024: $264 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614 · Education: $15.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.26 |
| Education | $15.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $113.62 | 2019-2025 | |
| Tris Pharma INC | $92.59 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $91.62 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $65.25 | 2024-2025 | Qelbree |
| Seqirus USA INC | $63.33 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $46.51 | 2019-2024 | Gardasil 9, Vaxelis, Rotateq |
| Neos Therapeutics, LP | $42.39 | 2019 | |
| Krystal Biotech INC | $38.30 | 2024 | Vyjuvek |
| Genzyme Corporation | $36.58 | 2019 | |
| Corium, LLC | $32.68 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $31.89 | 2019-2020 | |
| Glaxosmithkline, LLC. | $29.75 | 2019-2023 | Pediarix, Bexsero, Rotarix |
| Sanofi Pasteur INC. | $25.91 | 2023 | |
| Alexion Pharmaceuticals, INC. | $24.87 | 2024 | Strensiq |
| Prugen, INC. Pharmaceuticals | $21.51 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $20.93 | 2024 | Xelstrym, Secuado |
| Sanofi-Aventis U.S. LLC | $20.73 | 2025 | |
| Roche Diagnostics Corporation | $20.03 | 2019 | |
| Cranial Technologies, INC | $19.72 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.81 | 2024 | |
| Collegium Pharmaceutical, INC. | $18.15 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $17.19 | 2024 | Ycanth |
| Otsuka America Pharmaceutical, INC. | $15.80 | 2019 | |
| Cipher Pharmaceuticals US LLC | $15.55 | 2025 | Spinosad, Natroba |
| Vertical Pharmaceuticals, LLC | $14.29 | 2019 | |
| Aytu Biopharma, INC. | $13.67 | 2024 | Karbinal |
| Lnhc, INC | $13.46 | 2025 | Zelsuvmi |
| Organon LLC | $13.00 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Emery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.